Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle
- PMID: 6492693
- DOI: 10.1007/BF01725704
Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle
Abstract
The effects of K+-canrenoate (Aldactone pro inj.) and its metabolite canrenone on isometric force of contraction were measured in isolated guinea-pig and human papillary muscle preparations driven electrically at a frequency of 1 Hz. In guinea-pig hearts both substances exerted a concentration-dependent negative inotropic effect; the IC50 of K+-canrenoate and canrenone were 129 +/- 22 mumol l-1 (n = 5) and 85 +/- 11 mumol l-1 (n = 12), respectively. At the maximally tested concentration canrenone (250 mumol l-1) and K+-canrenoate (1,000 mumol l-1) reduced force of contraction by 68 +/- 4% (n = 12) and 83 +/- 3% (n = 5), respectively. The negative inotropic effects of canrenone and K+-canrenoate were not affected by 10 mumol l-1 atropine. The negative inotropic effect of canrenone was also not affected by 14 mumol l-1 aldosterone, but canrenone (10 mumol l-1 diminished the maximal positive inotropic effect of dihydro-ouabain from 554 +/- 75% (n = 4) to 269 +/- 39% (n = 4) of the predrug value. In human heart muscles K+-canrenoate and canrenone also exerted a concentration-dependent negative inotropic effect. K+-canrenoate (1,000 mumol l-1) and canrenone (250 mumol l-1) reduced force of contraction by 57 +/- 7% (n = 8) and 67 +/- 2% (n = 6), respectively. A positive inotropic effect of both substances was never observed. It is concluded that the improvement of cardiac performance after application of aldosterone antagonists observed in patients cannot be explained by a direct effect on the heart. K+-canrenoate and canrenone are devoid of any direct cardiotonic action. Instead, K+-canrenoate and canrenone have direct negative inotropic effects at high concentrations.
Similar articles
-
Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate.J Cardiovasc Pharmacol. 1996 Oct;28(4):519-25. doi: 10.1097/00005344-199610000-00007. J Cardiovasc Pharmacol. 1996. PMID: 8891876
-
Effects of canrenone on aorta and right ventricle of the rat.J Cardiovasc Pharmacol. 2001 May;37(5):540-7. doi: 10.1097/00005344-200105000-00006. J Cardiovasc Pharmacol. 2001. PMID: 11336105
-
Muscarinic receptors mediate negative and positive inotropic effects in mammalian ventricular myocardium: differentiation by agonists.Br J Pharmacol. 1987 Jan;90(1):81-90. doi: 10.1111/j.1476-5381.1987.tb16827.x. Br J Pharmacol. 1987. PMID: 2434180 Free PMC article.
-
Mechanism of the antimineralocorticoid effects of spirolactones.Kidney Int. 1981 Jul;20(1):1-6. doi: 10.1038/ki.1981.97. Kidney Int. 1981. PMID: 7029118 Review. No abstract available.
-
Ouabain-inhibiting activity of aldosterone antagonists.Steroids. 1995 Jan;60(1):110-3. doi: 10.1016/0039-128x(94)00005-w. Steroids. 1995. PMID: 7792794 Review.
Cited by
-
The negative inotropic action of canrenone is mediated by L-type calcium current blockade and reduced intracellular calcium transients.Br J Pharmacol. 2009 Sep;158(2):580-7. doi: 10.1111/j.1476-5381.2009.00329.x. Epub 2009 Aug 6. Br J Pharmacol. 2009. PMID: 19663883 Free PMC article.
-
The interaction of canrenone with the Na+,K+ pump in human red blood cells.Naunyn Schmiedebergs Arch Pharmacol. 1985 May;329(3):311-5. doi: 10.1007/BF00501886. Naunyn Schmiedebergs Arch Pharmacol. 1985. PMID: 2991778